Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
https://doi.org/10.17650/1818-8346-2022-17-2-141-150
Abstract
Proteasome inhibitors and immunomodulators (IMiDs), primarily bortezomib and lenalidomide, are essential components of treatment for both newly diagnosed and relapsed/refractory multiple myeloma (MM), producing high response rates and resulting in improved overall survival. However, bortezomib often induces a dose-limiting toxicity in the form of peripheral neuropathy (PN). Neurotoxicity often affects patient’s quality of life and requires dose modification or withdrawal of therapy, with a possible effect on the overall response. A prompt recognition of predisposing factors (such as diabetes mellitus, vitamin B12 deficiencies, or viral infections) and appearance of signs and symptoms, through a periodic neurological assessment with appropriate scales, is extremely important. Usually, bortezomib-induced PN is a sensory axonopathy characterized by numbness, tingling, and severe neuropathic pain in stocking and glove distribution while motor neuropathy is less frequently observed. Dose adjustment of bortezomib could be necessary during treatment. Anticonvulsants (pregabalin, gabapentin, carbamazepine, etc.) and tricyclic antidepressants (amitriptyline) are most often used to relieve neurological pain. In this review we focus on the clinical manifestations of bortezomibinduced PN, current understanding of the pathophysiological mechanisms as well as clinical and pharmacological aspects of prevention and management this complication. New proteasome inhibitors such as ixazomib and carfilzomib do not have the neurotoxicity of bortezomib. An early switch within the class of proteasome inhibitors from bortezomib to oral ixazomib appears to be an important approach to prevent severe PN. Our own clinical case of an early switch from bortezomib-based induction to IRd triplet (ixazomib, lenalidomide, dexamethasone) is cited as an illustration of the success of this approach.
About the Authors
S. V. Semochkin
P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiological Center, Ministry of Health of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
125284, Moscow, 2nd Botkinskiy Proezd, 3
117997, Moscow, Ostrovityanova St., 1
M. V. Solovyev
National Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
125167, Moscow, Novyy Zykovskiy Proezd, 4
L. P. Mendeleeva
National Research Center for Hematology, Ministry of Health of Russia
Russian Federation
Russian Federation
125167, Moscow, Novyy Zykovskiy Proezd, 4
References
1. Mendeleeva L.P., Votiakova O.M., Rekhtina I.G. et al. Multiple myeloma. Sovremennaya onkologiya = Journal of Modern Oncology 2020;22(4):6–28. (In Russ.) DOI:10.26442/18151434.2020.4.200457.
2. Luchinin A.S., Semochkin S.V., Minaeva N.V. et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Onkogematologiya = Oncohematology 2017;12(3):50–6. (In Russ.). DOI:10.17650/1818-8346201712-3-50-56.
3. Kanas G., Clark O., Keeven K. et al. Estimate of multiple myeloma patients by line of therapy in the USA: populationlevel projections 2020–2025. National Future Oncol 2021;17(8):921–30. DOI:10.2217/fon-2020-0970.
4. Skvortsova N.V., Pospelova T.I., Nechunaeva I.N. et al. Antitumor activity of bortesomib retreatment in relapsed or refractory multiple myeloma patients. Sibirskiy nauchnyy meditsinskiy zhurnal = Siberian Scientific Medical Journal 2013;33(1):76–81. (In Russ.).
5. Bessmeltsev S.S., Karyagina E.V., Stelmashenko L.V. et al. Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (Velcade). Onkogematologiya = Oncohematology 2008;52(3):52–62. (In Russ.).
6. Leone C., Federico V., La Cesa S. et al. An observational study assessing peripheral neuropathy related to multiple myeloma. Neurol Sci 2016;37(7):1141–3. DOI:10.1007/s10072-016-2542-9.
7. Ballegaard M., Nelson L.M., Gimsing P. Comparing neuropathy in multiple myeloma and AL amyloidosis. J Peripher Nerv Syst 2021;26(1):75–82. DOI:10.1111/jns.12428.
8. Dispenzieri A., Kyle R.A. Neurological aspects of multiple myeloma and related disorders. Best Pract Res Clin Haematol 2005;18(4):673–88. DOI:10.1016/j.beha.2005.01.024.
9. Zyrina G.V., Slyusar T.A. Clinical-psychological features of pain syndrome in multiple myeloma. Meditsinskiy alfavit = Medical Alphabet 2020;(22):26–9. (In Russ.). DOI:10.33667/2078-5631-2020-22-26-29.
10. Dalakas M.C. Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies. Ther Adv Neurol Disord 2018;11:1756285617746640. DOI:10.1177/1756285617746640.
11. Dispenzieri A. POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96(7): 872–88. DOI:10.1002/ajh.26240.
12. Piradov M.A., Suponeva N.A., Ginzberg M.A. et al. POEMS-syndrome: a literature review and case reports. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = The Korsakov’s Journal of Neurology and Psychiatry 2014;114(4):4–10. (In Russ.).
13. Dedov I.I., Shestakova M.V., Vikulova O.K. et al. Diabetes mellitus in Russian Federation: prevalence, morbidity, mortality, parameters of glycaemic control and structure of hypoglycaemic therapy according to the Federal Diabetes Register, status 2017. Sakharnyy diabet = Diabetes Mellitus 2018;21(3):144–59. (In Russ.). DOI:10.14341/DM9686.
14. Braschi C., Doucette J., Chariet A. Characteristics of vitamin B12 deficiency in patients with plasma cell disorders. Clin Lymphoma Myeloma Leuk 2017;17(12):e65–9. DOI:10.1016/j.clml.2017.07.001.
15. Stubblefield M.D., Burstein H.J., Burton A.W. et al. NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw 2009;7(S5):S1–26. DOI:10.6004/jnccn.2009.0078.
16. Selvy M., Kerckhove N., Pereira B. et al. Prevalence of chemotherapy-induced peripheral neuropathy in multiple myeloma patients and its impact on quality of life: a single center cross-sectional study. Front Pharmacol 2021;12:637593. DOI:10.3389/fphar.2021.637593.
17. Stepanova N.V., Machyulaytene E.R., Salogub G.N., Melnikova E.V. Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review. Onkogematologiya = Oncohematology 2009;4(1):21–8. (In Russ.).
18. Iakovlev A.A., Iakovleva M.V. Clinical features of peripheral neuropathy in paraproteinemic hemoblastosis. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova = The Korsakov’s Journal of Neurology and Psychiatry 2014;114(10):5–8. (In Russ.).
19. Velasco R., Alberti P., Bruna J. et al. Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment. J Peripher Nerv Syst 2019;24(S2):S52–62. DOI:10.1111/jns.12338.
20. Semochkin S.V. New proteasome inhibitors in the management of multiple myeloma. Onkogematologiya = Oncohematology 2019;14(2):29–40. (In Russ.). DOI:10.17650/18188346-2019-14-2-29-40.
21. Schmidt M.F., Gan Z.Y., Komander D., Dewson G. Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities. Cell Death Differ 2021;28(2):570–90. DOI:10.1038/s41418-020-00706-7.
22. Yan W., Wu Z., Zhang Y. et al. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy. Biomed Pharmacother 2021;142:112068. DOI:10.1016/j.biopha.2021.112068.
23. Richardson P.G., Sonneveld P., Schuster M.W., et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol 2009;144(6):895–903. DOI:10.1111/j.1365-2141.2008.07573.x.
24. Arnulf B., Pylypenko H., Grosicki S. et al. Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 2012;97(12):1925–8. DOI:10.3324/haematol.2012.067793.
25. Dimopoulos M.A., Moreau P., Palumbo A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016;17(1):27–38. DOI:10.1016/S1470-2045(15)00464-7.
26. Sonneveld P., Schmidt-Wolf I., van der Holt B. et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol 2012;30(24):2946–55. DOI:10.1200/JCO.2011.39.6820.
27. Mateos M.V., Dimopoulos M.A., Cavo M. et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 2018;378(6): 518–28. DOI:10.1056/NEJMoa1714678.
28. Loprinzi C.L., Lacchetti C., Bleeker J. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–48. DOI:10.1200/JCO.20.01399.
29. Li Y., Lustberg M.B., Hu S. Emerging pharmacological and non-pharmacological therapeutics for prevention and treatment of chemotherapy-induced peripheral neuropathy. Cancers (Basel) 2021;13(4):766. DOI:10.3390/cancers13040766.
30. Zakhariya O.I., Drobyshev V.A., Pospelova T.I. Application of dynamic electrical neurostimulation in the pain management in multiple myeloma patients with drug-induced peripheral neuropathy. Journal of Siberian Medical Sciences 2018;3:4–10. (In Russ.).
31. Moreau P., Masszi T., Grzasko N. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 2016;374(17):1621–34. DOI:10.1056/NEJMoa1516282.
32. Manda S., Yimer H.A., Noga S.J. et al. feasibility of long-term proteasome inhibition in multiple myeloma by in-class transition from bortezomib to ixazomib. Clin Lymphoma Myeloma Leuk 2020;20(11):e910–25. DOI:10.1016/j.clml.2020.06.024.
33. Hulin C., de la Rubia J., Dimopoulos M.A. et al. Bortezomib retreatment for relapsed and refractory multiple myeloma in realworld clinical practice. Health Sci Rep 2019;2(1):e104. DOI:10.1002/hsr2.104.
Review
For citations:
Semochkin S.V., Solovyev M.V., Mendeleeva L.P. Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Oncohematology. 2022;17(2):141-150. (In Russ.) https://doi.org/10.17650/1818-8346-2022-17-2-141-150
Views:
9672
Email this article 